Board Mod:
microcaps
Asst Mods:
Kachingpdx1
Last Post: 03/27/2023 7:05:03 AM
Board Marks: 82
Posts Today: 0
Board Views Today: 140
Posted On: 12/30/2021 8:29:49 PM
Posted By: willtheoak
Re: rayludwiczak #8753
well, lookie here! looks like the patient has a pulse after all...from my nano email updates
NanoLogix End of Year Update
NanoLogix provides the following as information to recipients of the Corporate Newsletter and the general public.
Over the past twenty-plus months the Company has experienced events with significant influence on operations, development, and perception of the Company. We are taking aggressive steps to resolve this situation.
One negative factor involving the sale of FlatPack petri plates was unpredictable, unavoidable, and caused substantial harm to a huge number of US businesses, including NanoLogix. The suspension of classes for most schools due to the COVID-19 pandemic resulted in a notable reduction of our FlatPack sales to a major customer sector. At this point with students back in schools the situation is turning around.
A second event of significant consequence was the development of the Rapid Viral Assay (RVA) technology. This technology has enormous potential not only for rapid detection of COVID-19 but multiple other viruses and variants.
The third factor was a change in SEC regulations that shifted thousands of companies from tradable non-reporting Pink Sheet status to a much more difficult to trade “grey market” status. This shift has had a drastic effect on stock prices.
Those three events present challenges for NanoLogix. We are dealing with those in the following ways:
1) With the reopening of many schools, we are prepared to increase FlatPack petri production to satisfy rebounding market demand.
2) We are also preparing for FDA Registration in January 2022 in order to be authorized to sell to laboratories and other groups that use Petri plates for testing samples under FDA regulated conditions. The FDA registration will list the FlatPack, our currently produced product, along with the ELISA variants of the N-Assay and RVA technologies.
3) After discussions with the OTC, and determining they will not accept independent SEC filings in order to restore NanoLogix to tradable Pink Sheet status, we will begin providing OTC with financials, and accept the burden of a $10,000 yearly fee. This is required to restore the Company to tradable status.
An Exciting and Vital Development
We have received a proposal from a large and very well respected research and development corporation titled for "Development of a Rapid Viral Assay (RVA) Suitable for Detection of COVID-19 and Other Viruses". This work will be accomplished utilizing live virus samples of multiple strains of COVID-19. Our initial portion of the development costs for the proposal is roughly $500,000. We have begun raising that amount through the use of a mechanism offering a small net revenue interest percentage of potential RVA sales. We have already raised $150,000 from interested medical groups through use of that mechanism, and intend to raise the balance with no sale or dilution of stock.
Along with the research and development partner described above, we believe that the patented Rapid Viral Assay (RVA) represents the only technology with the ability to detect live virus and determine both infection status and contagiousness potential. Our commitment is to push this critical technological development forward with all our resources and focus—both due to the overwhelming need for such a capability, and because we expect to be able to access a vast market for use of what promises to be a leading tool for accurate and rapid viral diagnostics.
This update or press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Posted On: 07/20/2021 1:55:16 PM
Posted By: Eudius
Another Update with some more verbiage:
Second Rapid Viral Assay (RVA) Patent Granted
Technology can be configured to detect viruses including COVID19 and Variants, HIV, HPV, SARS, MERS, and others without limitation
We are pleased to announce the issuance of United States patent 11066712, "Rapid Viral Assay", for detection and diagnosis of COVID19 (SARS-2) and other viruses.
United States Patent: 11066712 (uspto.gov)
This is a Continuation-In-Part for the RVA Family of Technology initially granted with US Patent 10844442 on November 24, 2020
A further Continuation-In-Part application for an additional patent related to detection of spontaneous viral mutations and other claims was filed with the USPTO yesterday. This addition will be essential to strengthening an already strong patent. We know that the virus will continue to mutate. It is extremely important that our tests are designed to anticipate that the virus will mutate and that the test will be able to detect the mutation. This approach is in stark contrast to current testing strategies, which may need to be modified to fit the mutation after the mutation occurs.
Full details of the granted patent, with the complete list of granted claims, is available in the USPTO Patent Gazette Week 29 publication.
This information can be accessed by entering the patent number of 11066712 after following this link:
http://patentsgazette.uspto.gov/week29/
Posted On: 07/20/2021 12:39:21 PM
Posted By: Eudius
Re: Eudius #8433
Just received a 2nd email with the Patent Number corrected
This information can be accessed by entering the patent number of 11066712 after following this link:
http://patentsgazette.uspto.gov/week29/
Posted On: 07/20/2021 12:04:07 PM
Posted By: nanobuyer
This just arrived in my mailbox:
Second Rapid Viral Assay (RVA) ?Patent Granted
Technology can be configured to detect viruses including COVID19 and Variants, HIV, HPV, SARS, MERS, and others without limitation
We are pleased to announce the issuance of United States patent 1106612, "Rapid Viral Assay", for detection and diagnosis of COVID19 (SARS-2) and other viruses.
United States Patent: 11066712 (uspto.gov)
This is a Continuation-In-Part for the RVA Family of Technology initially granted with US Patent 10844442 on November 24, 2020
A further Continuation-In-Part application for an additional patent related to detection of spontanaeous viral mutations and other claims was filed with the USPTO yesterday.
Full details of the granted patent, with the complete list of granted claims, is available in the USPTO Patent Gazette Week 29 publication.
This information can be accessed by entering the patent number of 1106612 after following this link:
http://patentsgazette.uspto.gov/week29/
June 10,2021
Update on new SEC reporting requirements
We are pleased to announce we will be filing regular reports with the SEC on a voluntary basis. This process does not mean Nanologix is uplisting to a different status, the Company will remain a Pink Sheet company for the time being.
Research and Development on the Rapid Viral Assay (RVA) continues at a research university and additional information will be released this summer.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
April 12, 2021
NanoLogix Incorporated
Rapid Viral Assay technology further expansion achieved with Notice of Allowance for Issuance of Continuation-in-Part Patent with 20 approved claims
We are pleased to announce receipt of Notice Of Allowance for a second Rapid Viral Assay Patent from the US Patent Office. The notice is for a Continuation-In-Part filed on November 21, 2020 for the Parent Patent issued November 24, 2020. It involves further protection for 20 approved claims relating to methods and a range of additional viruses for which rapid and accurate detection is vital. These include, for example, Middle East Respiratory Syndrome (MERS).
Our strategy of filing additional Continuation-In-Part patent applications for the ongoing research for SARS2/COVID19 Rapid Viral Assay development taking place between NanoLogix and several critical partners is projected to continue. These entities include a diagnostic company, a research team at a significant university, and a developing collaboration with a highly regarded research organization. This strategy is well suited for the overall Intellectual Property family established with the 2020 grant of the Parent Patent 10844442 "Rapid Viral Assay". It not only provides expanded protection of our intellectual property, but further allows expansion and development of the RVA technology to fully exploit its potential for viral diagnostics, "without limitation" as stated In the original patent grant.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Bret Barnhizer
NanoLogix Inc
+1 330-534-0800
NanoLogix Incorporated
Mar 9,2021
NanoLogix Provides the following as an update on the Development and Use of the recently Patented COVID-19 Detection Technology.
The Company is pleased to announce the achievment of certain milestones in their initial phase of commercialization for the Rapid Viral Assay (RVA).
Those are:
1. Successful Detection of irradiated (inactive) COVID-19 virus and its associated Spike Protein.
2. Non-Detection of Heat-Killed COVID-19 virus.
3. Limits of Detection (LOD) in the range of 10 Nanograms per milliliter of sample in 20 minutes.
What do these mean?
The RVA, unlike PCR technology, detects the whole virus and will not react to the presence of dead or nonpathogenic viral particles. This essentially eliminates false positives. (More routine testing such as PCR is plagued by false positives, due to the inability of PCR to distinguish between fragments of inactive virus and intact virus.)
The low threshhold for detection (meaning the RVA is more sensitive than other common tests), reduces the potential for false negative readings.
The RVA, as a detector of whole virions, should be able to detect pathogenic mutations, or variants, for the targeted virus. This means that as the virus continues to mutate and evolve, the RVA does not have to be modified in order to continue to maintain its accuracy.
The RVA development research is currently focused upon adaptation to a cartridge format that will provide ease of use and affordability.
The RVA is the only technology we know that tests for the whole virus.
The RVA is the only technology we know that is capable of determining if an individual is contagious.
Further updates will be issued as warranted
Posted On: 12/02/2020 7:33:28 AM
Posted By: Eudius
Formal Press release
https://www.einpresswire.com/article/53188821...7bfCcu0GcI
Good Stuff!!!
Read More: https://investorshangout.com/post/view?id=597...z6fXhq2FAF
https://www.tribtoday.com/news/local-news/202...ts-patent/
Posted On: 11/24/2020 9:51:28 AM
Posted By: Sierra
Patent on USPTO
https://pdfpiw.uspto.gov/.piw?PageNum=0&d...Dbarnhizer
Posted On: 11/11/2020 10:01:38 AM
Posted By: willtheoak
Re: ronclaw47 #7484
Rapid COVID19 test ?Patent Update
Patent filed May 18 Grant and Issuance will Occur within Two Weeks
...and here it is
We are pleased to announce the patent for rapid viral testing and diagnosis is scheduled for grant and issuance by the United States Patent and Trademark Office (USPTO) in less than two weeks. Information on the patent should be published in the USPTO Official Gazette for Patents on November 24th. Prior to that date both an international patent application under the Patent Cooperation Treaty (PCT) and a Continuation In Part (CIP) will be filed to broaden both the geographic and technological scope of the Intellectual Property protection and to add additional aspects to the technology that have been discovered or invented since the original application date.
Full details of the granted patent, with the complete list of twenty-five granted claims will be available upon Gazette publication.
Posted On: 10/14/2020 11:21:55 AM
Posted By: Eudius
Another Email update:
NanoLogix Is Researching FDA EUA Requirements For COVID-19 Testing Related to Recently Allowed Patent
1st For Whole Virus Detection, 2nd For Antibody Detection
NanoLogix Welcomes David R. Barnhizer as Vice President For Strategic Analysis and Development
NanoLogix is researching FDA requirements for EUA's for two of the 25 covered claims in the recently allowed patent application focused upon Rapid Virus Detection. Now that there has been allowance for issue of the patent with all 25 claims allowed, NanoLogix can justify devoting resources to this process and specifics.
Upon successful results for work currently being performed by a third party to apply NanoLogix technology to a separate testing platform for COVID19 detection, other applications may follow. Once the patent is issued we will reveal the broad and detailed extent of allowed claims for this technology.
Within the next two weeks NanoLogix will be releasing a narrative detailing challenges that were presented to the Company from outside sources apparently opposed to either the technology development or the Company since our May release of the COVID19 news.
David Barnhizer is Professor of Law Emeritus at the Cleveland State University. He received law degrees from the Ohio State University where he graduated summa cum laude and from Harvard University where he was a Ford Foundation Urban Law Fellow, a CLEPR Clinical Teaching Fellow, and earned a Masters of Law degree. He was Articles Editor of the Ohio State Law Journal, and began his legal career as a Reginald Heber Smith Community Lawyer in Colorado with the Colorado Springs Legal Services Office.
He has been a Senior Research Fellow at the University of London's Institute for Advanced Legal Studies, a frequent Visiting Professor at the Westminster University School of Law in London, taught human rights and international environmental law in St. Petersburg, Russia in a joint program with St. Petersburg State University, and instructed in Harvard’s Intersession program in Trial Advocacy.
He has served as Senior Adviser in the International Program of the Natural Resources Defense Council (NRDC). He was a Senior Fellow with Earth Summit Watch, and a board member of the International Shrimp Action Network (ISANET) an international NGO network made up of more than twenty NGOs involved in environment, development and coastal zone management in developing countries. He was Executive Director of the Washington, DC-based Year 2000 Committee, and has consulted extensively with environmental and development organizations. These include the World Resources Institute, the International Institute for Environment and Development, the United Nations Development Program, the President’s Council on Environmental Quality, the World Bank, the United Nations Food and Agricultural Organization (FAO), the World Wildlife Fund, the Mongolian government, and the Center for Global Change.
In addition, he spent nine years as a member of the board of directors for Performance Capital Management, and was a strategic consultant for Sovonics Solar Systems, a subsidiary of British Petroleum. He also served as Rapporteur for the Foresight Capability Workshop of the Energy and Commerce Committee of the US House of Representatives and has worked on projects in conjunction with numerous federal agencies.
He has written over fifty law review articles and book chapters, and authored and edited a number of books, including The Warrior Lawyer, a work developing the strategic principles of Sun Tzu's Art of War and Musashi's A Book of Five Rings. Other books include Strategies for Sustainable Societies, Environment Cleveland, The Blues of a Revolution, two volumes on Effective Strategies for Protecting Human Rights, and Hypocrisy & Myth: The Hidden Order of the Rule of Law co-authored with Daniel Barnhizer.
The most recent book, co-authored with Michigan State University Professor of Law Daniel Barnhizer, is The Artificial Intelligence Contagion: Can Democracy Withstand the Imminent Transformation of Work, Wealth, and the Social Order? CONTAGION has been ranked as high as # 1 in Book Authority’s All-Time Top 100 books on Robotics and in the top ten in Book Authority’s All-Time list on artificial intelligence.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Read More: https://investorshangout.com/post/view?id=592...z6auJe5xBA
Posted On: 10/05/2020 10:05:37 AM
Posted By: nanobuyer
Update from the company:
NanoLogix Covid-19 Detection Test Update
Partial Funding received from NanoLogix Directors Options Exercise
NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system. Partial funding for the first phase of the feasibility assessment is being provided through NanoLogix Director and Chief Medical Officer Dr. Jonathan Faro and Director Dr. Sebastian Faro exercise of options for 3 million shares. Those exercised shares are restricted from trading for a period of one year from issuance
The Directors' action reflects their belief in the NanoLogix rapid viral detection technology and its potential.
Independent laboratory work in Houston on a separate phase and aspect of the testing technology will begin after initial results from the above-mentioned work.
Read More: https://investorshangout.com/post/view?id=591...z6a2wrRGCj
Friday, August 7, 2020 10:29:11 AM
Post#
6969
of 6989
(Total Views: 134)
Posted On: 08/07/2020 8:22:19 AM
Posted By: Eudius
Update
NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments
NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
While we have achieved results in less than one hour with our own laboratory work, indications from one of the entities are that the test can potentially be streamlined to the point where results may be obtained in as little as twenty minutes in a form that makes the test more user and consumer friendly. This projected ease of use positions the assay for potential home use if and when it is approved by the FDA.
NanoLogix has entered into mutual confidentiality agreements with both involved groups. We faithfully respect those agreements as essential to the success of business and technology development. In the past, when we have released information mentioning arrangements with others, such as the US EPA, the University of Texas Health Science Center in Houston, Battelle Biomedical research Center, and individuals recently employed or otherwise associated with NanoLogix, those groups began receiving calls and contacts from persons identifying themselves as shareholders of NanoLogix. The calls ranged from in subject from simple curiousity to demands to reveal the nature of the technology development and business relationship with NanoLogix. The effects were potentially damaging to NanoLogix and its interests, to include investors. We will not release further information regarding the recent associations until all parties are prepared to do so.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Read More: https://investorshangout.com/post/view?id=585...z6URlniueu
Posted On: 07/09/2020 12:59:26 PM
Posted By: Fibonacci233
NanoLogix Welcomes Dr. Sebastian Faro to its Board of Directors
Sebastian Faro, MD joins as Director to Assist with Development Efforts
NanoLogix is very pleased to announce that Sebastian Faro, M.D, Ph.D. has joined our Board of Directors. Dr. Faro brings over forty-five years of medical experience and an extensive body of knowledge concerning infectious diseases to the NanoLogix Science Advisory Board. Dr. Faro previously served as Chief of Obstetrics and Gynecology at LBJ Hospital in Houston, Texas and was Vice-Chair of the Obstetrics, Gynecology, and Reproductive Sciences Department at the University of Texas Health Science Center at Houston. Dr. Faro received his PhD in botany at the University of Iowa and completed his postdoctoral fellowship training at the New York Botanical Garden. He then completed medical school and residency training at Creighton University. He served as director of infectious disease at both Louisiana State University and the Baylor College of Medicine, and as Department Chair for the University of Kansas and Rush-Presbyterian-St. Luke's Medical Center.
Dr. Faro is not only a member of a number of professional societies, but also served as President of the Infectious Disease Society for Obstetrics and Gynecology. He has published at least 149 articles in peer-reviewed medical publications and served as Editor-in-Chief of Infectious Diseases in Obstetrics and Gynecology for 13 years. He is also an Editor of the current editions of the following textbooks: Infectious Diseases in Women; Benign Diseases of the Vulva and Vagina; and Infections in Pregnancy.
Dr. Faro stated " I am looking forward to working with NanoLogix as it puts its efforts into providing solutions to the testing problems existing with the Coronavirus Pandemic."
Read More: https://investorshangout.com/post/view?id=582...z6RlLBP54N
Posted On: 06/03/2020 5:00:23 PM
Posted By: Machiavelli20
Re: rayludwiczak #6382
The key is that the prior technologies were either ones that had a reasonably narrow competitive edge over ones that major companies and suppliers had already locked in and were receiving remittances of some sort (kickbacks) or was in a niche that those committed to PCR and other type technologies had a close enough edge that they could ignore the development.
This diagnostic technology is so accurate and comprehensive across a number of critical categories that there is nothing competitive --except when the others cheat and have to be sued for patent infringement. My mantra is that I trust no one. Virtually everyone can be bought when the $$ are enough. So, given the technology as Faro and James Rogers (long term Battelle) describes, there is no equivalent in a critical global emergency. NNLX possesses the tech and has filed for the provisional patent and EUA for it to gain legal protection, there is an incredible need for this specific patented technology in the US, Europe, China (steals), etc. so the reality is that one way or another through a large scale marketing partner or a longer term law suit NNLX "wins". Although experience keeps us from being insane, $.08 or .15, or .50 simply does not make sense. Although we live in an insane nonsensical world. So unless you have a need for $500-$1500 gain you would be nuts to bail. But go ahead.
Posted On: 06/03/2020 1:07:25 PM
Posted By: Eudius
https://www.prnewswire.com/news-releases/nano..._cleartime
Posted On: 05/31/2020 10:12:21 AM
Posted By: Sierra
Another email update. I'm sure everyone has seen the summary. Nice info but it won't move the SP up.
NanoLogix and COVID-19 Testing News
Realizing that many of our shareholders are from areas where they may not be aware of news coverage of NanoLogix developments, the Company is pleased to present the following links to articles written and interviews done during the month of May.
Warren Tribune:
https://www.tribtoday.com/news/local-news/202...d-19-test/
Youngstown Vindicator:
https://www.vindy.com/opinion/brenda-j-linert...ng-valley/
Youngstown Vindicator:
https://www.vindy.com/news/local-news/2020/05...f-viruses/
Channel 27 (CBS) Youngstown:
https://www.youtube.com/watch?v=LrPoqVAH1No
Fox News 13 Tampa:
https://www.youtube.com/watch?v=HVcSchmwXgc
The Youngstown Vindicator is now published by the Warren Tribune, so while we link to one example, duplicate articles can be found for the same dates for both newspapers.
Read More: https://investorshangout.com/post/view?id=578...z6OATHH9e9
new website: https://nanologix.com/
https://www.vindy.com/news/local-news/2020/05...f-viruses/
Posted On: 05/18/2020 12:35:54 PM
Posted By: Sierra
Re: ronclaw47 #6162
NanoLogix Sub 1-Hour Covid-19 Detection Test Now
Patent-Pending
Patent Application Filed Under New COVID-19 Prioritized Examination Pilot Program
NanoLogix is pleased to announce the filing of a patent application for use in the rapid testing for the Covid-19 virus. The application was filed under a new program instituted May 14th by the US Patent and Trademark Office. Now that Patent-Pending status has been obtained, we can reveal aspects of the technology that we were unable to mention in a prior update.
This Rapid Viral Assay is a modified ELISA technology that is not the same as our N-Assay modified ELISA.
While the initial focus for development was for the COVID-19 virus, it became obvious that the technology is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is "Without Limitation".
An additional aspect of the test is that for the Home-Test configuration, we anticipate the potential of 30-minute results using a nasopharyngeal swab sample or saliva.
Jonathan Faro, MD, PhD., our Chief Medical Officer stated "We are extremely excited over this technology development, as it is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19."
The US Patent Office program under which the filing was done can be accessed through the following link:
https://www.federalregister.gov/documents/202...program?
Read More: https://investorshangout.com/post/view?id=577...z6N0UZkNXc
Posted On: 05/05/2020 12:44:35 AM
Posted By: nmbr1stckpckr
MORE info regarding the latest update:
https://www.vindy.com/news/local-news/2020/05...d-locally/
$1.00 easy?
Read More: https://investorshangout.com/post/view?id=575...z6LfnjWpuT
Posted On: 05/04/2020 11:01:55 AM
Posted By: rayludwiczak
A better look:
http://nanologix.com/downloads/Nanonews-05-03-2020.pdf
Read More: https://investorshangout.com/post/view?id=575...z6LWkZEmto
Posted On: 03/16/2020 2:24:17 AM
Posted By: Kachingpdx1
https://www.youtube.com/watch?v=zMRrNY0pxfM
NanoLogix Update - COVID-19 Detection
Last week the Company was contacted by a respected U.S. Government Contractor regarding our N-Assay Technology and its potential Coronavirus (COVID-19) testing capabilities.
We were informed by the contractor that they will bear all costs of configuration and testing of the N-Assay at their facilities. Following the conversation, NanoLogix sent a letter agreeing in principle to the proposal, which was rapidly acknowledged, and is awaiting a formal agreement from the contractor.
NanoLogix will not be supplying any materials or personnel for this process and our sole participation is on an Intellectual Property (Patent) basis, stemming from the N-Assay patent issued in 2015.
We will not be involved in the potential production of test kits if the contractor determines from the testing that N-Assay kits should be used in the fight against this Coronavirus. Should that happen, it would be done by a recognized producer under license.
We are hopeful that the N-Assay and one additional Point-of Care test we are developing will be useful tools for rapid detection of any pathogens that are threats to health.
A recap of our late-February Update:
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014 and 2015, with <3.5 hours results, we do not have the resources to independently pursue development of a Coronavirus rapid test.
The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or days, and while an N-Assay test could potentially deliver results in minutes, it may not be viewed as worthwhile in a cost/benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work producing filled Petri plates and development work on Urinary Tract and Yeast Infection rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
Posted On: 02/28/2020 11:32:38 AM
Posted By: mitstevfel
Response to Coronavirus Queries both International and US
The Company continues to receive calls inquiring about Coronavirus (COVID-19) testing capabilities.
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014, we do not have the resources to pursue development of a Coronavirus rapid test. There are a small number of BioSafety Level 4 labs in the US (4+/-) where development work on dangerous viruses can be done and their calendars are booked months to years in advance with daily costs that can run into tens of thousands of dollars. The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or a day, and while a test we develop may potentially deliver results in minutes, it may not be viewed as worthwhile in a cost:benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work on Urinary Tract and Yeast Infections rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
Posted On: 01/31/2020 3:04:22 PM
Posted By: Eudius
Update:
NanoLogix Incorporated
Response to Coronavirus Questions From Shareholders
Given a number of queries from shareholders asking if our technology could be used for rapid detection of the current Coronavirus originating in Wuhan, China we felt the following response is necessary:
Based upon positive preliminary research performed in 2014 with the N-Assay on Ebola virus protein markers, we believe both the N-Assay and the new Screening test currently under development have the potential for use in rapid detection of the Coronavirus. That said, given our focus on refinement of both the Screening Test and N-Assay Rapid Diagnostic for Urinary Tract and other bacterial and yeast infections, our limited resources as a small biotechnology company, along with the demonstrated historical lack of interest from potential partners and funders during the Ebola outbreak, we currently have no intention of individually pursuing development for Coronavirus detection without the assistance and cooperation of well-funded entities.
Posted On: 01/14/2020 11:21:31 AM
Posted By: Eudius
NanoLogix PreTest Development Update
NanoLogix is pleased to provide an additional update on the
Screening/Pretest and its potential as a standalone test
An important aspect of the Bacteria and Yeast pretest revealed during Phase One development is the ability to detect and specifically identify Candida yeast infection in human fluids, with no cross-reactivity from other microorganisms. The importance of this is three-fold. The first aspect is that this Candida test is a FIVE-MINUTE TEST. The second is that it can be offered for consumer use in retail outlets, in addition to being used by clinicians for laboratories and medical offices. The third is that there is no other consumer test that specifically identifies Candida, and in doing so, we believe it will provide the ability for consumers to self-diagnose and treat a condition that affects a large percentage of the public.
The previous update from December is provided below for reference
The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).
This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.
This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.
The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.
The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria within minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
In our effort to secure additional funding to reach our goal of $3 million for development, expansion and marketing, we have been in contact with a number of non-NanoLogix-affiliated MDs who have expressed interest in the technology development. Those efforts will continue until we reach our funding requirements.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
A direct link to the PowerPoint is here:
http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx
It is also available on our website at: http://nanologix.com/
Posted On: 12/16/2019 1:58:04 PM
Posted By: Eudius
New Update
NanoLogix Update on Phase One PreTest Development
NanoLogix is pleased to provide an update on the development of a
Screening/Pretest for use in conjunction with the N-Assay Rapid Bacteria Diagnostic.
The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).
This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.
This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.
The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.
The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria within minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
In our effort to secure additional funding to reach our goal of $3 million for development, expansion and marketing, we have been in contact with a number of non-NanoLogix-affiliated MDs who have expressed interest in the technology development. Those efforts will continue until we reach our funding requirements.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
A direct link to the PowerPoint is here:
http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx
It is also available on our website at: http://nanologix.com/
Posted On: 08/21/2019 6:53:03 AM
Posted By: willtheoak
like a sleeping purple dinosaur, nanologix has awakened
NanoLogix Seeks $3 Million For Expansion and Development
Offers Net-Revenue Share of N-Assay Bacteria Diagnostic
NanoLogix is discussing with domestic and international investment groups, and is seeking additional interested parties, for an investment offer of a net-revenue interest share of the N-Assay Bacteria Diagnostic and its planned associated Pretest. In exchange for an investment of up to $3 million, NanoLogix proposes a five-year 3-5% net-revenue sharing arrangement beginning with the proposed marketing rollout of the N-Assay in 2021, following planned patient studies in Houston. The funds are to be used for company expansion, development, production and marketing for the N-Assay, Pretest, and FlatPack petri plate technologies. There is no stock issuance or dilution involved with the funding proposal.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
Posted On: 04/02/2019 12:44:58 PM
Posted By: Kachingpdx1
Update on N-Assay
Overview and Potential in Multi-billion Diagnostics Market
NanoLogix is pleased to add an important PowerPoint Presentation update to our January 2019 statement of coordinated bacteria pretest development activity with two Biotechnology firms.
The PowerPoint Presentation can be viewed on The NanoLogix website at: http://nanologix.com/
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
Further updates will occur as warranted.
Update on N-Assay Pretest Development 1-16-19 posted by Eudius
NIH Grant Application Submitted for
Pre-test Development Study
NanoLogix is pleased to provide this update to our August 2018 statement of coordinated development activity with a California-based Biotechnology firm. The planning for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic is proceeding, with staff selections completed, letters of recomendation from noted medical authorites written, and the submission last week of the grant application for the study to the NIH by our Silicon-Valley partner. The research study is planned for two major Houston hospitals, funded from both Federal Grants and a raise of investment capital.
The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.
The current focus of this NIH grant application is on Group B Streptoccus (GBS). We are currently discussng Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development.
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.
Further updates will occur as warranted.
Posted On: 10/26/2018 9:16:31 AM
Posted By: Fibonacci233
Nanologix Incorporated
New write up that will be posted on our new website soon for our patented diagnostic. Comments and interest welcomed:
Nanologix' N-Assay offers an innovative solutions to a major problem that has plagued physicians over the years.
In medicine, nothing gets a clinician's attention like sepsis. When one has seen a patient who had previously been doing just fine suddenly take a turn for the worse, management decisions must be made without hesitation. In the case of a septic patient, seconds mean the difference between life and death, and minutes are a luxury that neither the clinician nor the patient may afford. The post-operative patient, the post-partum patient, the ICU patient... any patient is at risk of encountering a virulent pathogen in the hospital, and without an astute clinician ready to respond, serious consequences will occur. It's not surprising that the Infectious Disease Society of America estimates just this year that treating infections cost 21 to 34 billion dollars annually, in the US alone.
Clinicians currently have two techniques at their disposal when treating a presumed infection -culture, and PCR. The traditional technique of culture is labor intensive, requires laboratory-trained personnel, and correctly obtained, viable material. Although this method is relatively inexpensive, it is incredibly time-consuming. Patients often find it hard to believe that obtaining a culture result and antibiotic sensitivity profile may take 5 days! While the clinician is waiting for the results, they are throwing everything they've got at the possible infection. This is truly an empiric approach, and here it pays to have an experienced clinician by your side.
The alternative method, PCR, is much faster, much more sensitive, but also much more expensive. This newer technique also costs a great deal more, and requires highly trained personnel to operate the devices. These machines also incur a large capital investment by the hospital, as well as annual maintenance. In spite of the strengths of PCR, it also has weaknesses -it is unable to differentiate the difference between live/dead bacteria, and can not provide estimates relating to the degree of the inoculum. This information is essential for the clinician in directing targeted therapy, so again, they are ultimately forced to rely on their experience when treating the patient.
Regardless of one's opinion as to whether culture or PCR is the better option, the data over the last few decades shows the depressing truth -neither option is offering us any real advantage. This is made clear when one looks at the development of antibiotic resistance. These bugs have continued to grow and evolve, and a few years ago, a gonorrhea "super-bug" was isolated -showing resistance to every antibiotic available. We are clearly losing the war against these single-cell enemies!
In answer to this major problem, we have developed and patented an approach that takes all of the advantages of both culture and PCR (specificity, sensitivity, speed, and accuracy as well as ease of use), and none of the disadvantages. This technique, termed the N-Assay, is an antibody-based assay that targets potentially any bacterial pathogen (and has also been seen to detect yeast), in as little as 30 minutes. In addition, when incubated for 6 hours, this test not only provides a bacterial identification, but also allows the clinician to determine which antibiotic will work in treating the infection. This test will dramatically shorten the amount of time required for a clinician to wait when treating the ill patient, and should ultimately save billions in healthcare spending. Furthermore, by more accurately targeting the right bacterium with the correct antibiotic, we should drastically reduce the incidence in antimicrobial resistance.
We have already used a pilot version of this test in detecting group B streptococcus colonization in pregnant women, and have won an award at an OB GYN conference when presenting our data. The clinicians see that this test has tremendous potential, and are eager for it to be available, as they simply need better methods to more accurate diagnose infection. With the right resources, we will be able to expand this test to additional bacterial pathogens, such as E. coli, Enterococcus, MRSA, and any other clinically relevant pathogen.
Posted On: 09/07/2018 10:21:03 AM
Posted By: LuckyDog111
Notice of Upcoming NanoLogix Website Revision
Request For Confirmation of Continuing Interest From Newsletter Subscribers
NanoLogix is pleased to announce the Company website will be extensively revised and updated during September and October. The Company requests that those Newsletter Subscribers who are interested in continuing to receive updates of NanoLogix news through our iContact news service to send a confirmation email to: info@nanologix.com
This revision will enable the Company to significantly improve the website, providing the ability to respond rapidly to business events and to quickly furnishbusiness, technology, and hospital study updates.
8-20-18
NanoLogix Attends Series of Meetings In Houston
Preparation for Pre-test Development Study
NanoLogix is pleased to announce their attendance at a series of meetings in Houston with Drs. Sebastian and Jonathan Faro and the CEO of a California-based Biotechnology firm. The purpose of the meetings was for coordinating forces for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic. The meetings dealt with organization and staffing of a research study at two major Houston hospitals, funded from both Federal Grants and a raise of investment capital, and the specific personnel required for the successful execution of the study. The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
Dr. Jonathan Faro, PhD, MD stated: "These are incredibly exciting times for Nanologix. Seeing this study begin to crystallize has been invigorating, and it's wonderful to see other health care providers share an interest in our test, which is the leading diagnostic assay in bacterial identification and determination of antibiotic susceptibility. When speaking with nurses and other doctors, it's extraordinary to see their enthusiasm for the test --- we have found the right home for a study of this magnitude."
Jonathan Faro, MD Joins NanoLogix Board of Directors
Inbox
NanoLogix news@nanologix.com via icontactmail4.com
8:17 AM (12 hours ago)
NanoLogix Incorporated
NanoLogix Welcomes Dr. Jonathan Faro to Board of Directors
Jonathan Faro, PhD, MD, joins as Director of Medical Development
NanoLogix is pleased to announce the addition of Jonathan Faro, PhD, MD to the Company's Board of Directors. Dr. Faro is the co-inventor of the N-Assay modified ELISA bacteria-detection and identification technology and primary author of a number of published peer-reviewed research papers on the technology.
Dr. Faro's statement:
I am very excited to have joined the Board of Directors at NanoLogix, Inc. As the Director for Medical Development, I will serve a direct role in advocating for the goals of the company, and plan to work alongside the CEO and other board members to further development of the N-Assay. With their support, I have several goals that I aim to achieve. First and foremost, several studies need to be initiated. In addition to a large, multi-site study involving both private and academic centers, we will work on establishing multiple small-scale studies. Each of these will focus on the unique strengths of the N-Assay, so that clinicians will see that the assay is superior to anything currently on the market. We will focus on a four-pronged approach:
A) Speed of pathogen identification, providing clinicians with an accurate result far faster than that of culture,
Determination of antimicrobial resistance, so that clinicians may target their approach quickly, and begin seeing results faster than with any other technology on the market.
C) Offer clinicians novel approaches in treating infectious diseases, so that we stop the continued development of antimicrobial resistance.
D) Offer cheaper tests that do not increase the burden on national and international healthcare resources.
This final goal will have the benefit of taking NanoLogix not just through the US market, but will allow it to gain steady footing in the global market, which is necessary in order to truly help in limiting the spread of antimicrobial resistance, which currently claims approximately 700,000 lives per year. Although each of these goals will require considerable time, effort, and financial support, we have already begun the process of building in-roads with multiple well-respected clinical collaborators. These next several months certainly will be very exciting times for both myself and for NanoLogix!
NanoLogix Inc.
1- 330-534-0800
Email: info@nanologix.com // Website: http://www.nanologix.com
April 19,2018
Update On Petri FlatPack International Patent Status
Pursuant to NanoLogix' International Patent Offering
NanoLogix is pleased to announce payment yesterday (18 April 2018) of annuities for the FlatPack petri plate extended-life packaging patent in the EU and other granting countries. These annuity payments were made possible through a long time shareholder's efforts and the resulting receipt of funds by the Company from a new investor. The importance of the annuity payments cannot be overstated for the development of Nanologix --- sale and/or licensing of the FlatPack Patents internationally is projected to provide funding for the Company's expansion of agar-filled petri plate production in the USA and to complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
Without the potential to monetize the international patent assets the Company's development would depend upon domestic organic growth only, a process that while steady, would not meet NanoLogix' needs for rapid expansion.
Posted On: 04/12/2018 12:44:04 PM
Posted By: Kachingpdx1
Further European Patent Office Information on FlatPack Patent for Sale and Licensing
International Patent Offering
NanoLogix is pleased to announce receipt today (dated 11 April 2018) of notice from the European Patent Office (EPO) of the expiration of the nine-month opposition filing period for the FlatPack petri plate extended-life packaging patent (European Patent No. 2699491). The reason for this update from Nanologix is to inform all interested parties that out of the fourteen signatory countries chosen and paid for the registration and validation of the Flatpack Patent in early September 2017, prior to the receipt of this notice from the EPO, of the signatory states for the EU Patent treaty only the three non-EU member states of Sweden, Croatia, and Turkey had published notice of validation of the Flatpack patent in their respective patent bulletins.
Notice from the EPO states: "The entry in the Register of European Patents will be automatically generated by the electronic data processing system".
Further information from this notice: "This European patent has become wholly equivalent to a bundle of national patents in the designated states in which the patent was validated".
The publication in the EU Patent Registry is the essential and final step to enable NanoLogix to offer a fully registered and validated patent in the EU for license and/or sale. This step is in accordance with the Company's stated goal of using receipts from those efforts to fund expansion of agar-filled petri plate production in the US and complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
The Company is currently seeking to raise $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
Pending: Brazil, Canada
Posted On: 04/09/2018 11:28:36 AM
Posted By: Kachingpdx1
[4-9-18] Update on Patents Offered for Sale and Licensing, Grant Applications
International Patent Offering
NanoLogix is pleased to provide this update on the ongoing work on the sale and/or licensing of the international issued FlatPack patents, and filed and in-process applications to the National Institutes of Health, The National Science Foundation and BARDA
We have had interest in the technology from companies in France, Spain, Turkey, Serbia, South Africa, and China. The interest varies from licensing arrangements, purchase, and through direct representation of our products.
The Company is currently in the process of raising $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
Pending: Brazil, Canada
Grant Applications
One grant application has been filed with the National Institutes of Health (NIH) and two additional are planned with The National Science Foundation (NSF) and the Biomedical Advance Research and Development Authority (BARDA). Two of the applications are for funding for a pre-test for use with the N-Assay modified ELISA diagnostic and the BARDA application is for the use of the N-Assay for diagnostics of bio-threat agents.
As stated with the previous update from November, while there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.
[11-27-17] Update on Patents Offered for Sale, UTI Presentation at CAOG, and NSF Grant Application-see post 4050 11-27-17
International Patent Offering
NanoLogix is pleased to provide this update on the ongoing work on the sale of the European and China issued FlatPack patents, the poster presentation dealing with the seriousness of the threat from Urinary Tract Infections (UTI) with the need for new rapid methods for diagnostics for UTI infections, and an in-process application to the National Science Foundation for a $1.5 million grant.
Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses it
Posted By: willtheoak
Re: rayludwiczak #8753
well, lookie here! looks like the patient has a pulse after all...from my nano email updates
NanoLogix End of Year Update
NanoLogix provides the following as information to recipients of the Corporate Newsletter and the general public.
Over the past twenty-plus months the Company has experienced events with significant influence on operations, development, and perception of the Company. We are taking aggressive steps to resolve this situation.
One negative factor involving the sale of FlatPack petri plates was unpredictable, unavoidable, and caused substantial harm to a huge number of US businesses, including NanoLogix. The suspension of classes for most schools due to the COVID-19 pandemic resulted in a notable reduction of our FlatPack sales to a major customer sector. At this point with students back in schools the situation is turning around.
A second event of significant consequence was the development of the Rapid Viral Assay (RVA) technology. This technology has enormous potential not only for rapid detection of COVID-19 but multiple other viruses and variants.
The third factor was a change in SEC regulations that shifted thousands of companies from tradable non-reporting Pink Sheet status to a much more difficult to trade “grey market” status. This shift has had a drastic effect on stock prices.
Those three events present challenges for NanoLogix. We are dealing with those in the following ways:
1) With the reopening of many schools, we are prepared to increase FlatPack petri production to satisfy rebounding market demand.
2) We are also preparing for FDA Registration in January 2022 in order to be authorized to sell to laboratories and other groups that use Petri plates for testing samples under FDA regulated conditions. The FDA registration will list the FlatPack, our currently produced product, along with the ELISA variants of the N-Assay and RVA technologies.
3) After discussions with the OTC, and determining they will not accept independent SEC filings in order to restore NanoLogix to tradable Pink Sheet status, we will begin providing OTC with financials, and accept the burden of a $10,000 yearly fee. This is required to restore the Company to tradable status.
An Exciting and Vital Development
We have received a proposal from a large and very well respected research and development corporation titled for "Development of a Rapid Viral Assay (RVA) Suitable for Detection of COVID-19 and Other Viruses". This work will be accomplished utilizing live virus samples of multiple strains of COVID-19. Our initial portion of the development costs for the proposal is roughly $500,000. We have begun raising that amount through the use of a mechanism offering a small net revenue interest percentage of potential RVA sales. We have already raised $150,000 from interested medical groups through use of that mechanism, and intend to raise the balance with no sale or dilution of stock.
Along with the research and development partner described above, we believe that the patented Rapid Viral Assay (RVA) represents the only technology with the ability to detect live virus and determine both infection status and contagiousness potential. Our commitment is to push this critical technological development forward with all our resources and focus—both due to the overwhelming need for such a capability, and because we expect to be able to access a vast market for use of what promises to be a leading tool for accurate and rapid viral diagnostics.
This update or press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Posted On: 07/20/2021 1:55:16 PM
Posted By: Eudius
Another Update with some more verbiage:
Second Rapid Viral Assay (RVA) Patent Granted
Technology can be configured to detect viruses including COVID19 and Variants, HIV, HPV, SARS, MERS, and others without limitation
We are pleased to announce the issuance of United States patent 11066712, "Rapid Viral Assay", for detection and diagnosis of COVID19 (SARS-2) and other viruses.
United States Patent: 11066712 (uspto.gov)
This is a Continuation-In-Part for the RVA Family of Technology initially granted with US Patent 10844442 on November 24, 2020
A further Continuation-In-Part application for an additional patent related to detection of spontaneous viral mutations and other claims was filed with the USPTO yesterday. This addition will be essential to strengthening an already strong patent. We know that the virus will continue to mutate. It is extremely important that our tests are designed to anticipate that the virus will mutate and that the test will be able to detect the mutation. This approach is in stark contrast to current testing strategies, which may need to be modified to fit the mutation after the mutation occurs.
Full details of the granted patent, with the complete list of granted claims, is available in the USPTO Patent Gazette Week 29 publication.
This information can be accessed by entering the patent number of 11066712 after following this link:
http://patentsgazette.uspto.gov/week29/
Posted On: 07/20/2021 12:39:21 PM
Posted By: Eudius
Re: Eudius #8433
Just received a 2nd email with the Patent Number corrected
This information can be accessed by entering the patent number of 11066712 after following this link:
http://patentsgazette.uspto.gov/week29/
Posted On: 07/20/2021 12:04:07 PM
Posted By: nanobuyer
This just arrived in my mailbox:
Second Rapid Viral Assay (RVA) ?Patent Granted
Technology can be configured to detect viruses including COVID19 and Variants, HIV, HPV, SARS, MERS, and others without limitation
We are pleased to announce the issuance of United States patent 1106612, "Rapid Viral Assay", for detection and diagnosis of COVID19 (SARS-2) and other viruses.
United States Patent: 11066712 (uspto.gov)
This is a Continuation-In-Part for the RVA Family of Technology initially granted with US Patent 10844442 on November 24, 2020
A further Continuation-In-Part application for an additional patent related to detection of spontanaeous viral mutations and other claims was filed with the USPTO yesterday.
Full details of the granted patent, with the complete list of granted claims, is available in the USPTO Patent Gazette Week 29 publication.
This information can be accessed by entering the patent number of 1106612 after following this link:
http://patentsgazette.uspto.gov/week29/
June 10,2021
Update on new SEC reporting requirements
We are pleased to announce we will be filing regular reports with the SEC on a voluntary basis. This process does not mean Nanologix is uplisting to a different status, the Company will remain a Pink Sheet company for the time being.
Research and Development on the Rapid Viral Assay (RVA) continues at a research university and additional information will be released this summer.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
April 12, 2021
NanoLogix Incorporated
Rapid Viral Assay technology further expansion achieved with Notice of Allowance for Issuance of Continuation-in-Part Patent with 20 approved claims
We are pleased to announce receipt of Notice Of Allowance for a second Rapid Viral Assay Patent from the US Patent Office. The notice is for a Continuation-In-Part filed on November 21, 2020 for the Parent Patent issued November 24, 2020. It involves further protection for 20 approved claims relating to methods and a range of additional viruses for which rapid and accurate detection is vital. These include, for example, Middle East Respiratory Syndrome (MERS).
Our strategy of filing additional Continuation-In-Part patent applications for the ongoing research for SARS2/COVID19 Rapid Viral Assay development taking place between NanoLogix and several critical partners is projected to continue. These entities include a diagnostic company, a research team at a significant university, and a developing collaboration with a highly regarded research organization. This strategy is well suited for the overall Intellectual Property family established with the 2020 grant of the Parent Patent 10844442 "Rapid Viral Assay". It not only provides expanded protection of our intellectual property, but further allows expansion and development of the RVA technology to fully exploit its potential for viral diagnostics, "without limitation" as stated In the original patent grant.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Bret Barnhizer
NanoLogix Inc
+1 330-534-0800
NanoLogix Incorporated
Mar 9,2021
NanoLogix Provides the following as an update on the Development and Use of the recently Patented COVID-19 Detection Technology.
The Company is pleased to announce the achievment of certain milestones in their initial phase of commercialization for the Rapid Viral Assay (RVA).
Those are:
1. Successful Detection of irradiated (inactive) COVID-19 virus and its associated Spike Protein.
2. Non-Detection of Heat-Killed COVID-19 virus.
3. Limits of Detection (LOD) in the range of 10 Nanograms per milliliter of sample in 20 minutes.
What do these mean?
The RVA, unlike PCR technology, detects the whole virus and will not react to the presence of dead or nonpathogenic viral particles. This essentially eliminates false positives. (More routine testing such as PCR is plagued by false positives, due to the inability of PCR to distinguish between fragments of inactive virus and intact virus.)
The low threshhold for detection (meaning the RVA is more sensitive than other common tests), reduces the potential for false negative readings.
The RVA, as a detector of whole virions, should be able to detect pathogenic mutations, or variants, for the targeted virus. This means that as the virus continues to mutate and evolve, the RVA does not have to be modified in order to continue to maintain its accuracy.
The RVA development research is currently focused upon adaptation to a cartridge format that will provide ease of use and affordability.
The RVA is the only technology we know that tests for the whole virus.
The RVA is the only technology we know that is capable of determining if an individual is contagious.
Further updates will be issued as warranted
Posted On: 12/02/2020 7:33:28 AM
Posted By: Eudius
Formal Press release
https://www.einpresswire.com/article/53188821...7bfCcu0GcI
Good Stuff!!!
Read More: https://investorshangout.com/post/view?id=597...z6fXhq2FAF
https://www.tribtoday.com/news/local-news/202...ts-patent/
Posted On: 11/24/2020 9:51:28 AM
Posted By: Sierra
Patent on USPTO
https://pdfpiw.uspto.gov/.piw?PageNum=0&d...Dbarnhizer
Posted On: 11/11/2020 10:01:38 AM
Posted By: willtheoak
Re: ronclaw47 #7484
Rapid COVID19 test ?Patent Update
Patent filed May 18 Grant and Issuance will Occur within Two Weeks
...and here it is
We are pleased to announce the patent for rapid viral testing and diagnosis is scheduled for grant and issuance by the United States Patent and Trademark Office (USPTO) in less than two weeks. Information on the patent should be published in the USPTO Official Gazette for Patents on November 24th. Prior to that date both an international patent application under the Patent Cooperation Treaty (PCT) and a Continuation In Part (CIP) will be filed to broaden both the geographic and technological scope of the Intellectual Property protection and to add additional aspects to the technology that have been discovered or invented since the original application date.
Full details of the granted patent, with the complete list of twenty-five granted claims will be available upon Gazette publication.
Posted On: 10/14/2020 11:21:55 AM
Posted By: Eudius
Another Email update:
NanoLogix Is Researching FDA EUA Requirements For COVID-19 Testing Related to Recently Allowed Patent
1st For Whole Virus Detection, 2nd For Antibody Detection
NanoLogix Welcomes David R. Barnhizer as Vice President For Strategic Analysis and Development
NanoLogix is researching FDA requirements for EUA's for two of the 25 covered claims in the recently allowed patent application focused upon Rapid Virus Detection. Now that there has been allowance for issue of the patent with all 25 claims allowed, NanoLogix can justify devoting resources to this process and specifics.
Upon successful results for work currently being performed by a third party to apply NanoLogix technology to a separate testing platform for COVID19 detection, other applications may follow. Once the patent is issued we will reveal the broad and detailed extent of allowed claims for this technology.
Within the next two weeks NanoLogix will be releasing a narrative detailing challenges that were presented to the Company from outside sources apparently opposed to either the technology development or the Company since our May release of the COVID19 news.
David Barnhizer is Professor of Law Emeritus at the Cleveland State University. He received law degrees from the Ohio State University where he graduated summa cum laude and from Harvard University where he was a Ford Foundation Urban Law Fellow, a CLEPR Clinical Teaching Fellow, and earned a Masters of Law degree. He was Articles Editor of the Ohio State Law Journal, and began his legal career as a Reginald Heber Smith Community Lawyer in Colorado with the Colorado Springs Legal Services Office.
He has been a Senior Research Fellow at the University of London's Institute for Advanced Legal Studies, a frequent Visiting Professor at the Westminster University School of Law in London, taught human rights and international environmental law in St. Petersburg, Russia in a joint program with St. Petersburg State University, and instructed in Harvard’s Intersession program in Trial Advocacy.
He has served as Senior Adviser in the International Program of the Natural Resources Defense Council (NRDC). He was a Senior Fellow with Earth Summit Watch, and a board member of the International Shrimp Action Network (ISANET) an international NGO network made up of more than twenty NGOs involved in environment, development and coastal zone management in developing countries. He was Executive Director of the Washington, DC-based Year 2000 Committee, and has consulted extensively with environmental and development organizations. These include the World Resources Institute, the International Institute for Environment and Development, the United Nations Development Program, the President’s Council on Environmental Quality, the World Bank, the United Nations Food and Agricultural Organization (FAO), the World Wildlife Fund, the Mongolian government, and the Center for Global Change.
In addition, he spent nine years as a member of the board of directors for Performance Capital Management, and was a strategic consultant for Sovonics Solar Systems, a subsidiary of British Petroleum. He also served as Rapporteur for the Foresight Capability Workshop of the Energy and Commerce Committee of the US House of Representatives and has worked on projects in conjunction with numerous federal agencies.
He has written over fifty law review articles and book chapters, and authored and edited a number of books, including The Warrior Lawyer, a work developing the strategic principles of Sun Tzu's Art of War and Musashi's A Book of Five Rings. Other books include Strategies for Sustainable Societies, Environment Cleveland, The Blues of a Revolution, two volumes on Effective Strategies for Protecting Human Rights, and Hypocrisy & Myth: The Hidden Order of the Rule of Law co-authored with Daniel Barnhizer.
The most recent book, co-authored with Michigan State University Professor of Law Daniel Barnhizer, is The Artificial Intelligence Contagion: Can Democracy Withstand the Imminent Transformation of Work, Wealth, and the Social Order? CONTAGION has been ranked as high as # 1 in Book Authority’s All-Time Top 100 books on Robotics and in the top ten in Book Authority’s All-Time list on artificial intelligence.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Read More: https://investorshangout.com/post/view?id=592...z6auJe5xBA
Posted On: 10/05/2020 10:05:37 AM
Posted By: nanobuyer
Update from the company:
NanoLogix Covid-19 Detection Test Update
Partial Funding received from NanoLogix Directors Options Exercise
NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system. Partial funding for the first phase of the feasibility assessment is being provided through NanoLogix Director and Chief Medical Officer Dr. Jonathan Faro and Director Dr. Sebastian Faro exercise of options for 3 million shares. Those exercised shares are restricted from trading for a period of one year from issuance
The Directors' action reflects their belief in the NanoLogix rapid viral detection technology and its potential.
Independent laboratory work in Houston on a separate phase and aspect of the testing technology will begin after initial results from the above-mentioned work.
Read More: https://investorshangout.com/post/view?id=591...z6a2wrRGCj
Friday, August 7, 2020 10:29:11 AM
Post#
6969
of 6989
(Total Views: 134)
Posted On: 08/07/2020 8:22:19 AM
Posted By: Eudius
Update
NanoLogix Sub 1-Hour Covid-19 Detection Test Further Developments
NanoLogix Begins Collaborative Efforts With Diagnostic Company and an Independent Laboratory
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test. Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
While we have achieved results in less than one hour with our own laboratory work, indications from one of the entities are that the test can potentially be streamlined to the point where results may be obtained in as little as twenty minutes in a form that makes the test more user and consumer friendly. This projected ease of use positions the assay for potential home use if and when it is approved by the FDA.
NanoLogix has entered into mutual confidentiality agreements with both involved groups. We faithfully respect those agreements as essential to the success of business and technology development. In the past, when we have released information mentioning arrangements with others, such as the US EPA, the University of Texas Health Science Center in Houston, Battelle Biomedical research Center, and individuals recently employed or otherwise associated with NanoLogix, those groups began receiving calls and contacts from persons identifying themselves as shareholders of NanoLogix. The calls ranged from in subject from simple curiousity to demands to reveal the nature of the technology development and business relationship with NanoLogix. The effects were potentially damaging to NanoLogix and its interests, to include investors. We will not release further information regarding the recent associations until all parties are prepared to do so.
This press release or update contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Read More: https://investorshangout.com/post/view?id=585...z6URlniueu
Posted On: 07/09/2020 12:59:26 PM
Posted By: Fibonacci233
NanoLogix Welcomes Dr. Sebastian Faro to its Board of Directors
Sebastian Faro, MD joins as Director to Assist with Development Efforts
NanoLogix is very pleased to announce that Sebastian Faro, M.D, Ph.D. has joined our Board of Directors. Dr. Faro brings over forty-five years of medical experience and an extensive body of knowledge concerning infectious diseases to the NanoLogix Science Advisory Board. Dr. Faro previously served as Chief of Obstetrics and Gynecology at LBJ Hospital in Houston, Texas and was Vice-Chair of the Obstetrics, Gynecology, and Reproductive Sciences Department at the University of Texas Health Science Center at Houston. Dr. Faro received his PhD in botany at the University of Iowa and completed his postdoctoral fellowship training at the New York Botanical Garden. He then completed medical school and residency training at Creighton University. He served as director of infectious disease at both Louisiana State University and the Baylor College of Medicine, and as Department Chair for the University of Kansas and Rush-Presbyterian-St. Luke's Medical Center.
Dr. Faro is not only a member of a number of professional societies, but also served as President of the Infectious Disease Society for Obstetrics and Gynecology. He has published at least 149 articles in peer-reviewed medical publications and served as Editor-in-Chief of Infectious Diseases in Obstetrics and Gynecology for 13 years. He is also an Editor of the current editions of the following textbooks: Infectious Diseases in Women; Benign Diseases of the Vulva and Vagina; and Infections in Pregnancy.
Dr. Faro stated " I am looking forward to working with NanoLogix as it puts its efforts into providing solutions to the testing problems existing with the Coronavirus Pandemic."
Read More: https://investorshangout.com/post/view?id=582...z6RlLBP54N
Posted On: 06/03/2020 5:00:23 PM
Posted By: Machiavelli20
Re: rayludwiczak #6382
The key is that the prior technologies were either ones that had a reasonably narrow competitive edge over ones that major companies and suppliers had already locked in and were receiving remittances of some sort (kickbacks) or was in a niche that those committed to PCR and other type technologies had a close enough edge that they could ignore the development.
This diagnostic technology is so accurate and comprehensive across a number of critical categories that there is nothing competitive --except when the others cheat and have to be sued for patent infringement. My mantra is that I trust no one. Virtually everyone can be bought when the $$ are enough. So, given the technology as Faro and James Rogers (long term Battelle) describes, there is no equivalent in a critical global emergency. NNLX possesses the tech and has filed for the provisional patent and EUA for it to gain legal protection, there is an incredible need for this specific patented technology in the US, Europe, China (steals), etc. so the reality is that one way or another through a large scale marketing partner or a longer term law suit NNLX "wins". Although experience keeps us from being insane, $.08 or .15, or .50 simply does not make sense. Although we live in an insane nonsensical world. So unless you have a need for $500-$1500 gain you would be nuts to bail. But go ahead.
Posted On: 06/03/2020 1:07:25 PM
Posted By: Eudius
https://www.prnewswire.com/news-releases/nano..._cleartime
Posted On: 05/31/2020 10:12:21 AM
Posted By: Sierra
Another email update. I'm sure everyone has seen the summary. Nice info but it won't move the SP up.
NanoLogix and COVID-19 Testing News
Realizing that many of our shareholders are from areas where they may not be aware of news coverage of NanoLogix developments, the Company is pleased to present the following links to articles written and interviews done during the month of May.
Warren Tribune:
https://www.tribtoday.com/news/local-news/202...d-19-test/
Youngstown Vindicator:
https://www.vindy.com/opinion/brenda-j-linert...ng-valley/
Youngstown Vindicator:
https://www.vindy.com/news/local-news/2020/05...f-viruses/
Channel 27 (CBS) Youngstown:
https://www.youtube.com/watch?v=LrPoqVAH1No
Fox News 13 Tampa:
https://www.youtube.com/watch?v=HVcSchmwXgc
The Youngstown Vindicator is now published by the Warren Tribune, so while we link to one example, duplicate articles can be found for the same dates for both newspapers.
Read More: https://investorshangout.com/post/view?id=578...z6OATHH9e9
new website: https://nanologix.com/
https://www.vindy.com/news/local-news/2020/05...f-viruses/
Posted On: 05/18/2020 12:35:54 PM
Posted By: Sierra
Re: ronclaw47 #6162
NanoLogix Sub 1-Hour Covid-19 Detection Test Now
Patent-Pending
Patent Application Filed Under New COVID-19 Prioritized Examination Pilot Program
NanoLogix is pleased to announce the filing of a patent application for use in the rapid testing for the Covid-19 virus. The application was filed under a new program instituted May 14th by the US Patent and Trademark Office. Now that Patent-Pending status has been obtained, we can reveal aspects of the technology that we were unable to mention in a prior update.
This Rapid Viral Assay is a modified ELISA technology that is not the same as our N-Assay modified ELISA.
While the initial focus for development was for the COVID-19 virus, it became obvious that the technology is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is "Without Limitation".
An additional aspect of the test is that for the Home-Test configuration, we anticipate the potential of 30-minute results using a nasopharyngeal swab sample or saliva.
Jonathan Faro, MD, PhD., our Chief Medical Officer stated "We are extremely excited over this technology development, as it is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19."
The US Patent Office program under which the filing was done can be accessed through the following link:
https://www.federalregister.gov/documents/202...program?
Read More: https://investorshangout.com/post/view?id=577...z6N0UZkNXc
Posted On: 05/05/2020 12:44:35 AM
Posted By: nmbr1stckpckr
MORE info regarding the latest update:
https://www.vindy.com/news/local-news/2020/05...d-locally/
$1.00 easy?
Read More: https://investorshangout.com/post/view?id=575...z6LfnjWpuT
Posted On: 05/04/2020 11:01:55 AM
Posted By: rayludwiczak
A better look:
http://nanologix.com/downloads/Nanonews-05-03-2020.pdf
Read More: https://investorshangout.com/post/view?id=575...z6LWkZEmto
Posted On: 03/16/2020 2:24:17 AM
Posted By: Kachingpdx1
https://www.youtube.com/watch?v=zMRrNY0pxfM
NanoLogix Update - COVID-19 Detection
Last week the Company was contacted by a respected U.S. Government Contractor regarding our N-Assay Technology and its potential Coronavirus (COVID-19) testing capabilities.
We were informed by the contractor that they will bear all costs of configuration and testing of the N-Assay at their facilities. Following the conversation, NanoLogix sent a letter agreeing in principle to the proposal, which was rapidly acknowledged, and is awaiting a formal agreement from the contractor.
NanoLogix will not be supplying any materials or personnel for this process and our sole participation is on an Intellectual Property (Patent) basis, stemming from the N-Assay patent issued in 2015.
We will not be involved in the potential production of test kits if the contractor determines from the testing that N-Assay kits should be used in the fight against this Coronavirus. Should that happen, it would be done by a recognized producer under license.
We are hopeful that the N-Assay and one additional Point-of Care test we are developing will be useful tools for rapid detection of any pathogens that are threats to health.
A recap of our late-February Update:
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014 and 2015, with <3.5 hours results, we do not have the resources to independently pursue development of a Coronavirus rapid test.
The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or days, and while an N-Assay test could potentially deliver results in minutes, it may not be viewed as worthwhile in a cost/benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work producing filled Petri plates and development work on Urinary Tract and Yeast Infection rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
Posted On: 02/28/2020 11:32:38 AM
Posted By: mitstevfel
Response to Coronavirus Queries both International and US
The Company continues to receive calls inquiring about Coronavirus (COVID-19) testing capabilities.
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014, we do not have the resources to pursue development of a Coronavirus rapid test. There are a small number of BioSafety Level 4 labs in the US (4+/-) where development work on dangerous viruses can be done and their calendars are booked months to years in advance with daily costs that can run into tens of thousands of dollars. The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or a day, and while a test we develop may potentially deliver results in minutes, it may not be viewed as worthwhile in a cost:benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work on Urinary Tract and Yeast Infections rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
Posted On: 01/31/2020 3:04:22 PM
Posted By: Eudius
Update:
NanoLogix Incorporated
Response to Coronavirus Questions From Shareholders
Given a number of queries from shareholders asking if our technology could be used for rapid detection of the current Coronavirus originating in Wuhan, China we felt the following response is necessary:
Based upon positive preliminary research performed in 2014 with the N-Assay on Ebola virus protein markers, we believe both the N-Assay and the new Screening test currently under development have the potential for use in rapid detection of the Coronavirus. That said, given our focus on refinement of both the Screening Test and N-Assay Rapid Diagnostic for Urinary Tract and other bacterial and yeast infections, our limited resources as a small biotechnology company, along with the demonstrated historical lack of interest from potential partners and funders during the Ebola outbreak, we currently have no intention of individually pursuing development for Coronavirus detection without the assistance and cooperation of well-funded entities.
Posted On: 01/14/2020 11:21:31 AM
Posted By: Eudius
NanoLogix PreTest Development Update
NanoLogix is pleased to provide an additional update on the
Screening/Pretest and its potential as a standalone test
An important aspect of the Bacteria and Yeast pretest revealed during Phase One development is the ability to detect and specifically identify Candida yeast infection in human fluids, with no cross-reactivity from other microorganisms. The importance of this is three-fold. The first aspect is that this Candida test is a FIVE-MINUTE TEST. The second is that it can be offered for consumer use in retail outlets, in addition to being used by clinicians for laboratories and medical offices. The third is that there is no other consumer test that specifically identifies Candida, and in doing so, we believe it will provide the ability for consumers to self-diagnose and treat a condition that affects a large percentage of the public.
The previous update from December is provided below for reference
The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).
This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.
This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.
The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.
The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria within minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
In our effort to secure additional funding to reach our goal of $3 million for development, expansion and marketing, we have been in contact with a number of non-NanoLogix-affiliated MDs who have expressed interest in the technology development. Those efforts will continue until we reach our funding requirements.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
A direct link to the PowerPoint is here:
http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx
It is also available on our website at: http://nanologix.com/
Posted On: 12/16/2019 1:58:04 PM
Posted By: Eudius
New Update
NanoLogix Update on Phase One PreTest Development
NanoLogix is pleased to provide an update on the development of a
Screening/Pretest for use in conjunction with the N-Assay Rapid Bacteria Diagnostic.
The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).
This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.
This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.
The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.
The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria within minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
In our effort to secure additional funding to reach our goal of $3 million for development, expansion and marketing, we have been in contact with a number of non-NanoLogix-affiliated MDs who have expressed interest in the technology development. Those efforts will continue until we reach our funding requirements.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
A direct link to the PowerPoint is here:
http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx
It is also available on our website at: http://nanologix.com/
Posted On: 08/21/2019 6:53:03 AM
Posted By: willtheoak
like a sleeping purple dinosaur, nanologix has awakened
NanoLogix Seeks $3 Million For Expansion and Development
Offers Net-Revenue Share of N-Assay Bacteria Diagnostic
NanoLogix is discussing with domestic and international investment groups, and is seeking additional interested parties, for an investment offer of a net-revenue interest share of the N-Assay Bacteria Diagnostic and its planned associated Pretest. In exchange for an investment of up to $3 million, NanoLogix proposes a five-year 3-5% net-revenue sharing arrangement beginning with the proposed marketing rollout of the N-Assay in 2021, following planned patient studies in Houston. The funds are to be used for company expansion, development, production and marketing for the N-Assay, Pretest, and FlatPack petri plate technologies. There is no stock issuance or dilution involved with the funding proposal.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
Posted On: 04/02/2019 12:44:58 PM
Posted By: Kachingpdx1
Update on N-Assay
Overview and Potential in Multi-billion Diagnostics Market
NanoLogix is pleased to add an important PowerPoint Presentation update to our January 2019 statement of coordinated bacteria pretest development activity with two Biotechnology firms.
The PowerPoint Presentation can be viewed on The NanoLogix website at: http://nanologix.com/
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
Further updates will occur as warranted.
Update on N-Assay Pretest Development 1-16-19 posted by Eudius
NIH Grant Application Submitted for
Pre-test Development Study
NanoLogix is pleased to provide this update to our August 2018 statement of coordinated development activity with a California-based Biotechnology firm. The planning for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic is proceeding, with staff selections completed, letters of recomendation from noted medical authorites written, and the submission last week of the grant application for the study to the NIH by our Silicon-Valley partner. The research study is planned for two major Houston hospitals, funded from both Federal Grants and a raise of investment capital.
The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.
The current focus of this NIH grant application is on Group B Streptoccus (GBS). We are currently discussng Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development.
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.
Further updates will occur as warranted.
Posted On: 10/26/2018 9:16:31 AM
Posted By: Fibonacci233
Nanologix Incorporated
New write up that will be posted on our new website soon for our patented diagnostic. Comments and interest welcomed:
Nanologix' N-Assay offers an innovative solutions to a major problem that has plagued physicians over the years.
In medicine, nothing gets a clinician's attention like sepsis. When one has seen a patient who had previously been doing just fine suddenly take a turn for the worse, management decisions must be made without hesitation. In the case of a septic patient, seconds mean the difference between life and death, and minutes are a luxury that neither the clinician nor the patient may afford. The post-operative patient, the post-partum patient, the ICU patient... any patient is at risk of encountering a virulent pathogen in the hospital, and without an astute clinician ready to respond, serious consequences will occur. It's not surprising that the Infectious Disease Society of America estimates just this year that treating infections cost 21 to 34 billion dollars annually, in the US alone.
Clinicians currently have two techniques at their disposal when treating a presumed infection -culture, and PCR. The traditional technique of culture is labor intensive, requires laboratory-trained personnel, and correctly obtained, viable material. Although this method is relatively inexpensive, it is incredibly time-consuming. Patients often find it hard to believe that obtaining a culture result and antibiotic sensitivity profile may take 5 days! While the clinician is waiting for the results, they are throwing everything they've got at the possible infection. This is truly an empiric approach, and here it pays to have an experienced clinician by your side.
The alternative method, PCR, is much faster, much more sensitive, but also much more expensive. This newer technique also costs a great deal more, and requires highly trained personnel to operate the devices. These machines also incur a large capital investment by the hospital, as well as annual maintenance. In spite of the strengths of PCR, it also has weaknesses -it is unable to differentiate the difference between live/dead bacteria, and can not provide estimates relating to the degree of the inoculum. This information is essential for the clinician in directing targeted therapy, so again, they are ultimately forced to rely on their experience when treating the patient.
Regardless of one's opinion as to whether culture or PCR is the better option, the data over the last few decades shows the depressing truth -neither option is offering us any real advantage. This is made clear when one looks at the development of antibiotic resistance. These bugs have continued to grow and evolve, and a few years ago, a gonorrhea "super-bug" was isolated -showing resistance to every antibiotic available. We are clearly losing the war against these single-cell enemies!
In answer to this major problem, we have developed and patented an approach that takes all of the advantages of both culture and PCR (specificity, sensitivity, speed, and accuracy as well as ease of use), and none of the disadvantages. This technique, termed the N-Assay, is an antibody-based assay that targets potentially any bacterial pathogen (and has also been seen to detect yeast), in as little as 30 minutes. In addition, when incubated for 6 hours, this test not only provides a bacterial identification, but also allows the clinician to determine which antibiotic will work in treating the infection. This test will dramatically shorten the amount of time required for a clinician to wait when treating the ill patient, and should ultimately save billions in healthcare spending. Furthermore, by more accurately targeting the right bacterium with the correct antibiotic, we should drastically reduce the incidence in antimicrobial resistance.
We have already used a pilot version of this test in detecting group B streptococcus colonization in pregnant women, and have won an award at an OB GYN conference when presenting our data. The clinicians see that this test has tremendous potential, and are eager for it to be available, as they simply need better methods to more accurate diagnose infection. With the right resources, we will be able to expand this test to additional bacterial pathogens, such as E. coli, Enterococcus, MRSA, and any other clinically relevant pathogen.
Posted On: 09/07/2018 10:21:03 AM
Posted By: LuckyDog111
Notice of Upcoming NanoLogix Website Revision
Request For Confirmation of Continuing Interest From Newsletter Subscribers
NanoLogix is pleased to announce the Company website will be extensively revised and updated during September and October. The Company requests that those Newsletter Subscribers who are interested in continuing to receive updates of NanoLogix news through our iContact news service to send a confirmation email to: info@nanologix.com
This revision will enable the Company to significantly improve the website, providing the ability to respond rapidly to business events and to quickly furnishbusiness, technology, and hospital study updates.
8-20-18
NanoLogix Attends Series of Meetings In Houston
Preparation for Pre-test Development Study
NanoLogix is pleased to announce their attendance at a series of meetings in Houston with Drs. Sebastian and Jonathan Faro and the CEO of a California-based Biotechnology firm. The purpose of the meetings was for coordinating forces for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic. The meetings dealt with organization and staffing of a research study at two major Houston hospitals, funded from both Federal Grants and a raise of investment capital, and the specific personnel required for the successful execution of the study. The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
Dr. Jonathan Faro, PhD, MD stated: "These are incredibly exciting times for Nanologix. Seeing this study begin to crystallize has been invigorating, and it's wonderful to see other health care providers share an interest in our test, which is the leading diagnostic assay in bacterial identification and determination of antibiotic susceptibility. When speaking with nurses and other doctors, it's extraordinary to see their enthusiasm for the test --- we have found the right home for a study of this magnitude."
Jonathan Faro, MD Joins NanoLogix Board of Directors
Inbox
NanoLogix news@nanologix.com via icontactmail4.com
8:17 AM (12 hours ago)
NanoLogix Incorporated
NanoLogix Welcomes Dr. Jonathan Faro to Board of Directors
Jonathan Faro, PhD, MD, joins as Director of Medical Development
NanoLogix is pleased to announce the addition of Jonathan Faro, PhD, MD to the Company's Board of Directors. Dr. Faro is the co-inventor of the N-Assay modified ELISA bacteria-detection and identification technology and primary author of a number of published peer-reviewed research papers on the technology.
Dr. Faro's statement:
I am very excited to have joined the Board of Directors at NanoLogix, Inc. As the Director for Medical Development, I will serve a direct role in advocating for the goals of the company, and plan to work alongside the CEO and other board members to further development of the N-Assay. With their support, I have several goals that I aim to achieve. First and foremost, several studies need to be initiated. In addition to a large, multi-site study involving both private and academic centers, we will work on establishing multiple small-scale studies. Each of these will focus on the unique strengths of the N-Assay, so that clinicians will see that the assay is superior to anything currently on the market. We will focus on a four-pronged approach:
A) Speed of pathogen identification, providing clinicians with an accurate result far faster than that of culture,
Determination of antimicrobial resistance, so that clinicians may target their approach quickly, and begin seeing results faster than with any other technology on the market. C) Offer clinicians novel approaches in treating infectious diseases, so that we stop the continued development of antimicrobial resistance.
D) Offer cheaper tests that do not increase the burden on national and international healthcare resources.
This final goal will have the benefit of taking NanoLogix not just through the US market, but will allow it to gain steady footing in the global market, which is necessary in order to truly help in limiting the spread of antimicrobial resistance, which currently claims approximately 700,000 lives per year. Although each of these goals will require considerable time, effort, and financial support, we have already begun the process of building in-roads with multiple well-respected clinical collaborators. These next several months certainly will be very exciting times for both myself and for NanoLogix!
NanoLogix Inc.
1- 330-534-0800
Email: info@nanologix.com // Website: http://www.nanologix.com
April 19,2018
Update On Petri FlatPack International Patent Status
Pursuant to NanoLogix' International Patent Offering
NanoLogix is pleased to announce payment yesterday (18 April 2018) of annuities for the FlatPack petri plate extended-life packaging patent in the EU and other granting countries. These annuity payments were made possible through a long time shareholder's efforts and the resulting receipt of funds by the Company from a new investor. The importance of the annuity payments cannot be overstated for the development of Nanologix --- sale and/or licensing of the FlatPack Patents internationally is projected to provide funding for the Company's expansion of agar-filled petri plate production in the USA and to complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
Without the potential to monetize the international patent assets the Company's development would depend upon domestic organic growth only, a process that while steady, would not meet NanoLogix' needs for rapid expansion.
Posted On: 04/12/2018 12:44:04 PM
Posted By: Kachingpdx1
Further European Patent Office Information on FlatPack Patent for Sale and Licensing
International Patent Offering
NanoLogix is pleased to announce receipt today (dated 11 April 2018) of notice from the European Patent Office (EPO) of the expiration of the nine-month opposition filing period for the FlatPack petri plate extended-life packaging patent (European Patent No. 2699491). The reason for this update from Nanologix is to inform all interested parties that out of the fourteen signatory countries chosen and paid for the registration and validation of the Flatpack Patent in early September 2017, prior to the receipt of this notice from the EPO, of the signatory states for the EU Patent treaty only the three non-EU member states of Sweden, Croatia, and Turkey had published notice of validation of the Flatpack patent in their respective patent bulletins.
Notice from the EPO states: "The entry in the Register of European Patents will be automatically generated by the electronic data processing system".
Further information from this notice: "This European patent has become wholly equivalent to a bundle of national patents in the designated states in which the patent was validated".
The publication in the EU Patent Registry is the essential and final step to enable NanoLogix to offer a fully registered and validated patent in the EU for license and/or sale. This step is in accordance with the Company's stated goal of using receipts from those efforts to fund expansion of agar-filled petri plate production in the US and complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
The Company is currently seeking to raise $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
Pending: Brazil, Canada
Posted On: 04/09/2018 11:28:36 AM
Posted By: Kachingpdx1
[4-9-18] Update on Patents Offered for Sale and Licensing, Grant Applications
International Patent Offering
NanoLogix is pleased to provide this update on the ongoing work on the sale and/or licensing of the international issued FlatPack patents, and filed and in-process applications to the National Institutes of Health, The National Science Foundation and BARDA
We have had interest in the technology from companies in France, Spain, Turkey, Serbia, South Africa, and China. The interest varies from licensing arrangements, purchase, and through direct representation of our products.
The Company is currently in the process of raising $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
Pending: Brazil, Canada
Grant Applications
One grant application has been filed with the National Institutes of Health (NIH) and two additional are planned with The National Science Foundation (NSF) and the Biomedical Advance Research and Development Authority (BARDA). Two of the applications are for funding for a pre-test for use with the N-Assay modified ELISA diagnostic and the BARDA application is for the use of the N-Assay for diagnostics of bio-threat agents.
As stated with the previous update from November, while there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.
[11-27-17] Update on Patents Offered for Sale, UTI Presentation at CAOG, and NSF Grant Application-see post 4050 11-27-17
International Patent Offering
NanoLogix is pleased to provide this update on the ongoing work on the sale of the European and China issued FlatPack patents, the poster presentation dealing with the seriousness of the threat from Urinary Tract Infections (UTI) with the need for new rapid methods for diagnostics for UTI infections, and an in-process application to the National Science Foundation for a $1.5 million grant.
Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses it
Nanologix Inc (NNLX) Stock Message Board
